FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry is actively applying quantitative systems pharmacology (QSP) to make internal decisions and guide drug development. To facilitate the eventual development of a common framework for assessing the credibility of QSP models for clinical drug development, scientists from US Food and Drug Administration and the pharmaceutical industry organized a full-day virtual Scientific Exchange on July 1, 2020. An assessment form was used to ensure consistency in the evaluation process. Among the cases presented, QSP was applied to various therapeutic areas. Applications mostly focused on phase 2 dose selection. Model transparency, including details on expert knowledge and data used for model development, was identified as a major factor for robust model assessment. The case studies demonstrated some commonalities in the workflow of QSP model development, calibration, and validation but differ in the size, scope, and complexity of QSP models, in the acceptance criteria for model calibration and validation, and in the algorithms/approaches used for creating virtual patient populations. Though efforts are being made to build the credibility of QSP models and the confidence is increasing in applying QSP for internal decisions at the clinical stages of drug development, there are still many challenges facing QSP application to late stage drug development. The QSP community needs a strategic plan that includes the ability and flexibility to Adapt, to establish Common ex…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A methodology for performing global uncertainty and sensitivity analysis in systems biology
Marino, S., Hogue, I. B., Ray, C. J., & Kirschner, D. E. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.04.011 · Cited by 2,999
An effective screening design for sensitivity analysis of large models
Campolongo, F., Cariboni, J., & Saltelli, A. (2007) · Environmental Modelling & Software · doi:10.1016/j.envsoft.2006.10.004 · Cited by 2,011
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
Zhang, X., Trame, M., Lesko, L., & Schmidt, S. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.6 · Cited by 467
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Papp, K., Gordon, K., Thaçi, D., Morita, A., Gooderham, M., Foley, P., Girgis, I. G., Kundu, S., & Banerjee, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1806382 · Cited by 420
Rich, P., Sigurgeirsson, B., Thaçi, D., Ortonne, J. ‐., Paul, C. F., Schopf, R. E., Morita, A., Roseau, K., Harfst, E., Guettner, A., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12112 · Cited by 244
Cited by
Virtual Populations for Quantitative Systems Pharmacology Models
Cheng, Y., Straube, R., Alnaif, A. E., Huang, L., Leil, T. A., & Schmidt, B. J. (2022) · Methods in Molecular Biology · doi:10.1007/978-1-0716-2265-0_8 · Cited by 54
Self-citationModernizing Preclinical Drug Development: The Role of New Approach Methodologies
Mehta, K., Maaß, C., Cucurull-Sanchez, L., Pichardo‐Almarza, C., Subramanian, K., Androulakis, I. P., Gobburu, J. V. S., Schaller, S., & Sherwin, C. M. T. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00162 · Cited by 56
Wang, H., Zhao, C., Santa-Maria, C. A., Emens, L. A., & Popel, A. S. (2022) · iScience · doi:10.1016/j.isci.2022.104702 · Cited by 48
An industry perspective on current QSP trends in drug development
Cucurull-Sanchez, L. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09905-y · Cited by 37
Current practices for QSP model assessment: an IQ consortium survey
Chan, J. R., Allen, R., Boras, B. W., Cabal, A., Damian, V., Gibbons, F. D., Gulati, A., Hosseini, I., Kearns, J. D., Saito, R., et al. (2022) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-022-09811-1 · Cited by 27
“Model transparency, including details on expert knowledge and data used for model development, has been identified elsewhere as a major factor for robust model assessment [3].”
InfluentialSelf-citation
Metadata
- Authors
- Bai, J. P. F., Schmidt, B. J., Gadkar, K. G., Damian, V., Earp, J. C., Friedrich, C., van der Graaf, P. H., Madabushi, R., Musante, C. J., Naik, K., Rogge, M., & Zhu, H.
- Affiliations
- United States Food and Drug Administration (US)
- Bristol-Myers Squibb (United States) (US)
- Genentech (US)
- GlaxoSmithKline (United States) (US)
- Rosa (United States) (US)
- Pfizer (United States) (US)
- Corresponding author
- Bai, Jane P. F.
- Schmidt, Brian J.
- Gadkar, Kapil G.
- ORCID
- Venue
- The AAPS Journal
- Published
- 2021-04-30
- Volume
- 23
- Issue
- 3
- Pages
- 60-60
- ISSN
- 1550-7416 (ISSN-L)
- OpenAlex
- W3158242131
- Cited by
- 38
- References
- 33
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 6 · 2023: 4 · 2022: 11 · 2021: 2
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- The AAPS Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- quantitative systems pharmacology, clinical development, model calibration and validation, model transparency, virtual patient population, late-stage drug development, drug labeling
- MeSH terms
- Intersectoral Collaboration, Drug Development, Congresses as Topic, Drug Industry, Humans, Models, Biological, United States, United States Food and Drug Administration, Systems Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective. https://app.cochat.ai/papers/10.1208/s12248-021-00585-x
- The paper
- Bai, J. P. F., Schmidt, B. J., Gadkar, K. G., Damian, V., Earp, J. C., Friedrich, C., van der Graaf, P. H., Madabushi, R., Musante, C. J., Naik, K., Rogge, M., & Zhu, H. (2021). FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective. The AAPS Journal. https://doi.org/10.1208/s12248-021-00585-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.